Meet molnupiravir, Merck’s Thor-inspired pill that hammers COVID In Phase III trial, the drug smashed hospitalization and death rate by about half.

The Food and Drug Administration on Thursday authorized the use of Merck's molnupiravir pill for treating COVID-19, the second such emergency use authorization in two days.

LONDON — Regulators in Britain granted approval to the experimental drug molnupiravir from U.S. pharmaceutical giant Merck on Thursday, marking the first authorization from a public health body ...

Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19 ...

Merck & Ridgeback to Present Data Demonstrating LAGEVRIO (molnupiravir) Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo ...

FDA authorizes Pfizer pill to treat COVID-19 as Omicron hits all 50 sates 11:46. The Food and Drug Administration announced Thursday it had authorized molnupiravir, a drug produced by Merck and ...

That molnupiravir can mutate SARS-CoV-2 to death has been demonstrated in the controlled conditions of a petri dish and lab animal cages, leading Merck to test it in covid-19 patients in clinical ...

Molnupiravir, Merck’s investigational antiviral pill, is the first oral treatment that has shown promise in treating Covid-19.

Merck has another Phase 3 clinical trial (1332 participants) in progress testing molnupiravir (800mg twice daily for 5 days) treatment of adults who reside with a person infected with COVID-19.

Merck & Co said on Thursday it expects its 2022 sales to increase as much as 18 percent over last year, mostly on sales of its new COVID-19 pill, molnupiravir.

Britain has granted a conditional authorization to Merck's coronavirus antiviral, the first pill shown to successfully treat COVID-19. It is the first country to OK the treatment, although it was ...

Merck has granted a royalty-free license for its promising Covid-19 pill to a United Nations-backed nonprofit in a deal that would allow the drug to be manufactured and sold cheaply in the poorest ...